Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.

Wang HL, Wang YY, Liu XG, Kuo SH, Liu N, Song QY, Wang MW.

J Alzheimers Dis. 2016;51(1):45-55. doi: 10.3233/JAD-150734. Review.

2.

24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.

Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Björkhem I, von Bergmann K, Heun R.

J Psychiatr Res. 2002 Jan-Feb;36(1):27-32.

PMID:
11755458
3.

Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: candidate marker of brain health.

Leoni V, Solomon A, Lövgren-Sandblom A, Minthon L, Blennow K, Hansson O, Wahlund LO, Kivipelto M, Björkhem I.

J Alzheimers Dis. 2013;36(4):739-47. doi: 10.3233/JAD-130035.

PMID:
23666171
4.

Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?

Leoni V, Shafaati M, Salomon A, Kivipelto M, Björkhem I, Wahlund LO.

Neurosci Lett. 2006 Apr 10-17;397(1-2):83-7. Epub 2006 Jan 6.

PMID:
16406316
5.

ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease.

Yassine HN, Feng Q, Chiang J, Petrosspour LM, Fonteh AN, Chui HC, Harrington MG.

J Am Heart Assoc. 2016 Feb 12;5(2). pii: e002886. doi: 10.1161/JAHA.115.002886.

6.

Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.

Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.

J Alzheimers Dis. 2014;42(3):777-88. doi: 10.3233/JAD-132216.

PMID:
24916543
7.

T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.

Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A.

Neuroimage Clin. 2015 Feb 26;7:598-604. doi: 10.1016/j.nicl.2015.02.016. eCollection 2015.

8.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.

J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

PMID:
25391385
9.

Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.

Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.

Exp Gerontol. 2017 Dec 15;100:45-53. doi: 10.1016/j.exger.2017.10.013. Epub 2017 Oct 17.

PMID:
29054536
10.

Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.

Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.

J Alzheimers Dis. 2016 Jul 29;54(1):157-68. doi: 10.3233/JAD-160176.

PMID:
27472875
11.

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN.

Alzheimers Res Ther. 2016 Apr 27;8(1):17. doi: 10.1186/s13195-016-0182-1.

12.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

13.

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A.

J Alzheimers Dis. 2015;45(4):1077-88. doi: 10.3233/JAD-142952.

PMID:
25649653
14.

The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.

Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.

J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11.

15.

Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.

Mroczko B, Groblewska M, Zboch M, Muszyński P, Zajkowska A, Borawska R, Szmitkowski M, Kornhuber J, Lewczuk P.

J Alzheimers Dis. 2015;43(3):1031-7. doi: 10.3233/JAD-141050.

PMID:
25159667
16.

Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.

Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller HJ, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perneczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F.

Neurobiol Aging. 2015 Feb;36(2):601-7. doi: 10.1016/j.neurobiolaging.2014.10.031. Epub 2014 Oct 31.

PMID:
25435336
17.

The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease.

Benussi L, Ghidoni R, Dal Piaz F, Binetti G, Di Iorio G, Abrescia P.

J Alzheimers Dis. 2017;56(2):825-833. doi: 10.3233/JAD-160930.

PMID:
27983556
18.

Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.

Mackin RS, Insel P, Zhang J, Mohlenhoff B, Galasko D, Weiner M, Mattsson N.

J Alzheimers Dis. 2015;43(3):1007-16. doi: 10.3233/JAD-141287.

19.

Multielectrode array analysis of cerebrospinal fluid in Alzheimer's disease versus mild cognitive impairment: a potential diagnostic and treatment biomarker.

Görtz P, Siebler M, Ihl R, Henning U, Luckhaus C, Supprian T, Lange-Asschenfeldt C.

Biochem Biophys Res Commun. 2013 May 3;434(2):293-7. doi: 10.1016/j.bbrc.2013.02.121. Epub 2013 Mar 26.

PMID:
23541573
20.

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.

Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P.

Alzheimers Res Ther. 2015 Dec 24;7:74. doi: 10.1186/s13195-015-0161-y.

Supplemental Content

Support Center